Trial Profile
A Phase 2a, Ascending Dose, Placebo-Controlled Study to Evaluate the Safety of CTX-100 (Formerly ETX-100) Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs CTX 100 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- 03 Dec 2019 Status changed from recruiting to completed.
- 17 Jun 2011 Planned end date changed from 1 Mar 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.
- 17 Dec 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.